TOKYO–(BUSINESS WIRE)–Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter “Elix”) and SEEDSUPPLY Inc. (CEO: Naoki Tarui / HQ: Kanagawa, hereinafter “SEEDSUPPLY”) hereby announce the start of joint research.
SEEDSUPPLY (https: //www.seedsupply.co.jp/) proposes an agile small molecule drug discovery process that uses ligand selection technology as a screening method for proprietary compounds. This technology can perform compound screening of any protein or RNA, thus providing drug discovery seeds for various drug discovery targets, including those for which measurement of biochemical activity is challenging. Additionally, a compound binding database constructed for specific drug discovery target classes will be used for target selection, improving the efficiency and success rate of drug discovery processes. Furthermore, the database presents the potential for wider application.
Elix (https://www.elix-inc.com/) is an artificial intelligence drug discovery company with the mission “Rethinking Drug Discovery”. To reduce cost and time while increasing the success rate of the drug discovery pipeline, Elix is focusing on using machine learning in projects targeting pharmaceutical companies, universities and research institutes. Elix has developed and released Elix Discovery™, the comprehensive AI drug discovery platform, offering everything from property prediction models and molecular design to consulting and implementation support in one package (https: //www .elix -inc.com/news/newsrelease/1620/). In addition to providing drug discovery support, Elix is also considering future in-house drug discovery.
In this joint research project, SEEDSUPPLY will use Elix’s proprietary AI technology with the aim of dramatically increasing the efficiency of screening processes. Elix will incorporate SEEDSUPPLY’s wealth of data, particularly its data on key drug discovery targets such as membrane proteins, into the AI training pipeline, thus advancing the technology for in silicon techniques to control compounds with superior properties.
Elix and SEEDSUPPLY aim to leverage their respective strengths to reduce the cost and time of small molecule drug discovery and address targets that have proven difficult for conventional drug discovery approaches.
Comments from Elix CEO Shinya Yuki
By combining the data obtained through SEEDSUPPLY’s proprietary technology and our proprietary AI models, we hope to find even more unique technological developments. We believe that this technology will enable great opportunities in screening very difficult targets at low cost in a short time and in efficient search of vast chemical spaces.
Comments from SEEDSUPPLY CEO Naoki Tarui
Our company’s complex link database is of the highest quality because all of its content has been measured using the same method. By combining it with Elix’s superior AI technology, we hope to create new developments in AI drug discovery technology.